Moreover, there are findings suggesting reduced IFN signatures in patients with severe COVID-19 (113), in contrast to the early and strong IFN responses found in antiviral responses of mild SARS-CoV-2 infection (114). The gene discussed is IFNA1; the disease is COVID-19.